Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

ranged from 2.4 to 2.9 log10 in the three dose groups studied. No patient at any dose level showed evidence of viral rebound while on ANA598 and there were no serious adverse events.
  • Reported 14-day Healthy Volunteer Study Results. In April 2009, Anadys reported results from a 14-day study of ANA598 in healthy volunteers. ANA598 was generally well-tolerated in all cohorts in the study with no serious adverse events. Three instances of mild-to-moderate rash were observed at the higher dose levels. Pharmacokinetic results from this trial confirmed the plasma half-life of ANA598 of approximately 24 hours, and demonstrated that steady-state levels of ANA598 in plasma are reached after six to seven days of dosing.
  • Dosing Completed in Long-Term Chronic Toxicology Studies. The dosing period is completed in two long-term, chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). At the 13-week interim, the toxicology profile of ANA598 in both species was very favorable. While 39-week data from the monkey study is not yet available, a preliminary assessment of the results from the 26-week study in rats indicates a similar profile to that seen in rats at 13 weeks, in which the only adverse finding was a marginal decrease in the rate of weight gain in females at 1000 mg/kg, the highest dose tested. Complete results from both studies are expected at the end of the third quarter 2009.
  • ANA773

    ANA773 is the Company's oral inducer of endogenous interferons that acts via the toll like receptor 7 (TLR7) pathway.

    • Phase I Clinical Trial in HCV. Nine patients have completed dosing at 2000 mg in the Company's trial of ANA773 in HCV patients, and the final patient is currently being dosed. During the second quarter the Company reported evidence of viral load reduction in a majority of patients wh
      '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
    8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
    9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
    10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
    11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
    (Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
    (Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
    (Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
    Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
    ... Oxford Biomedica,s,second attempt to dismiss Bavarian Nordic,s patent ... denying infringement, Oxford Biomedica,made yet another attempt to dismiss ... still evaluated in clinical trials. The court ruled,against Oxford ... the,substance of the patents. , ...
    ... 8 Sinovac Biotech Ltd. (Amex: SVA ), ... it will host a conference call on Friday, May 15, ... quarter financial results for the period ended March 31, 2009 ... conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). ...
    ... (Nasdaq: NVAX) today announced financial results for ... of $8.3 million, or $0.12 per share, for the first quarter ... $0.13 per share, for the first quarter of 2008. The ... of 2009 and ended the quarter with $25.6 million in cash ...
    Cached Biology Technology:The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 2Novavax Reports First Quarter 2009 Financial Results 3Novavax Reports First Quarter 2009 Financial Results 4Novavax Reports First Quarter 2009 Financial Results 5Novavax Reports First Quarter 2009 Financial Results 6Novavax Reports First Quarter 2009 Financial Results 7Novavax Reports First Quarter 2009 Financial Results 8
    (Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
    (Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
    (Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
    ... Houston Cullen College of Engineering has won a grant to ... disease safer and more effective. The grant goes to ... the National Science Foundation, it is valued at $330,000 for ... Abosch, an M.D./Ph.D a neurosurgeon with the University of Colorado ...
    ... more than a decade PETA and its affiliates ... organisations worldwide, providing the European Union (EU) and ... with technical expertise in modern, reliable, non-animal research ... PETA US, PETA UK and their European and ...
    ... that individuals with the highest metabolic rates within populations ... changes in their environments that could lead them to ... however should be constantly monitoring their opportunities for higher ... shows that variation in metabolic rates between individuals can ...
    Cached Biology News:Parkinson's Surgery Research wins NSF Grant 2PETA and its international affiliates launch not-for-profit international science company 2Gathering information about food is not top priority for individuals with high metabolisms 2
    Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
    ... monitoring Aldolase tests. 2 levels of ... manufacturing values at 4 ± 2 ... 30-day shelf life once opened ... 1: 3 x 3 ml; Level ...
    Human VEGF-D Biotinylated MAb (Clone 78923)...
    Mouse Wnt-11 Affinity Purified Polyclonal Ab...
    Biology Products: